Despite the numerous advancements in Alzheimer’s disease research, diagnosing the condition before symptoms manifest remains a significant challenge. However, a recent study conducted by a team from the US has identified a promising breakthrough: the discovery of an “earliest-yet biomarker” that precedes the onset of Alzheimer’s disease.
The study, conducted on animals, has shed light on a protein called PSD-95, which is specific to neurons and plays a crucial role in promoting excitatory activity at synapses. Elevated levels of PSD-95 were found to be associated with increased neuronal activity, resembling seizure-like activity, in the early stages of Alzheimer’s disease.
Researchers observed that the presence of amyloid-beta (Aβ), a hallmark of Alzheimer’s disease, induced higher levels of PSD-95. By inhibiting PSD-95, the team was able to reduce synaptic activity and mitigate seizure-like behavior in mice, even before the formation of Aβ plaques or the onset of memory problems.
Lead researcher Nien-Pei Tsai, a molecular biologist at the University of Illinois Urbana-Champaign, believes that PSD-95 could serve as an early biomarker for Alzheimer’s disease or elevated seizure susceptibility. This discovery could pave the way for new diagnostic tools and therapeutic targets for the disease.
While translating these findings into clinical applications will require further research, the study offers hope for early detection and intervention in Alzheimer’s disease. The researchers are optimistic that targeting PSD-95 could slow down the progression of symptoms and potentially improve outcomes for patients affected by this devastating condition.
As the scientific community continues to unravel the complexities of Alzheimer’s disease, this study marks a significant step towards understanding its underlying mechanisms and developing effective treatments.
Read Now:India Tops Global Doping Offenders List: WADA Report
